The small molecule macrocyclic
lactone ivermectin, approved by the US Food and Drug Administration for
parasitic infections, has received renewed attention in the last eight years due to its apparent exciting potential as an
antiviral. It was identified in a high-throughput chemical screen as inhibiting recognition of the nuclear localizing Human Immunodeficiency Virus-1 (HIV-1)
integrase protein by the host heterodimeric
importin (
IMP) α/β1 complex, and has since been shown to bind directly to IMPα to induce conformational changes that prevent its normal function in mediating nuclear import of key viral and host
proteins. Excitingly, cell culture experiments show robust
antiviral action towards HIV-1, dengue virus (DENV), Zika virus, West Nile virus, Venezuelan equine encephalitis virus, Chikungunya virus, Pseudorabies virus, adenovirus, and SARS-CoV-2 (COVID-19). Phase III human clinical trials have been completed for DENV, with >50 trials currently in progress worldwide for SARS-CoV-2. This mini-review discusses the case for
ivermectin as a host-directed broad-spectrum
antiviral agent for a range of viruses, including SARS-CoV-2.